Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 positive |
| Therapy | DB-1310 |
| Indication/Tumor Type | prostate cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 positive | prostate cancer | sensitive | DB-1310 | Preclinical - Pdx | Actionable | In a preclinical study, DB-1310 inhibited tumor growth in ERBB3 (HER3)-positive prostate cancer patient-derived xenograft (PDX) models (PMID: 38632563). | 38632563 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38632563) | DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors. | Full reference... |